Widely used:Recently Viewed
Clear All
Today’s Range
52 Week Range
Liquidity
Market cap
$1 Mln
P/E Ratio
--
P/B Ratio
0.32
Industry P/E
--
Debt to Equity
0
ROE
-7.45 %
ROCE
--
Div. Yield
0 %
Book Value
--
EPS
-2.27
CFO
$-19.60 Mln
EBITDA
$-23.39 Mln
Net Profit
$-26.37 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Aclarion Inc (ACON)
| -100.00 | -82.26 | -99.99 | -100.00 | -- | -- | -- |
|
BSE Sensex*
| -2.20 | 1.05 | -1.94 | 6.14 | 9.77 | 20.67 | 10.48 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
|
|---|---|---|
|
Aclarion Inc (ACON)
| -95.38 | -65.52 |
|
S&P Small-Cap 600
| 7.01 | 13.89 |
|
BSE Sensex
| 8.10 | 18.74 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 37.18 | 10,372.39 | 21.06 | 23.13 | |
| 32.45 | 12,882.28 | -- | -28.77 | |
| 110.07 | 10,998.29 | 33.53 | 14.16 | |
| 73.45 | 7,759.66 | 34.18 | 19.71 |
Aclarion, Inc. operates as a healthcare technology company in the United States. The company uses magnetic resonance spectroscopy (MRS) and proprietary biomarkers to optimize clinical treatments. It develops NOCISCAN software application, a... non-invasively analyze the chemical makeup of intervertebral discs in the spine. The company also develops NOCISCAN Post-Processor Suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado. Address: 8181 Arista Place, Broomfield, CO, United States, 80021 Read more
Executive Chairman
Dr. Jeffrey John Thramann M.D.
Executive Chairman
Dr. Jeffrey John Thramann M.D.
Headquarters
Broomfield, CO
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Aclarion Inc (ACON) stood at $ 4 Mln as on 30-Sep-24
The share price of Aclarion Inc (ACON) is $0.80 (NASDAQ) as of 20-Mar-2025 16:28 EDT. Aclarion Inc (ACON) has given a return of -100% in the last 1 years.
Aclarion Inc (ACON) has a market capitalisation of $ 1 Mln as on 20-Mar-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Aclarion Inc (ACON) is 0.32 times as on 20-Mar-2025, a 88% discount to its peers’ median range of 2.71 times.
Since, TTM earnings of Aclarion Inc (ACON) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Aclarion Inc (ACON) and enter the required number of quantities and click on buy to purchase the shares of Aclarion Inc (ACON).
Aclarion, Inc. operates as a healthcare technology company in the United States. The company uses magnetic resonance spectroscopy (MRS) and proprietary biomarkers to optimize clinical treatments. It develops NOCISCAN software application, a non-invasively analyze the chemical makeup of intervertebral discs in the spine. The company also develops NOCISCAN Post-Processor Suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado. Address: 8181 Arista Place, Broomfield, CO, United States, 80021
The CEO & director of Dr. Jeffrey John Thramann M.D.. is Aclarion Inc (ACON), and CFO & Sr. VP is Dr. Jeffrey John Thramann M.D..
There is no promoter pledging in Aclarion Inc (ACON).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,168
|
|
|
1,141
|
|
|
1,072
|
|
|
1,045
|
| Aclarion Inc (ACON) | Ratios |
|---|---|
|
Return on equity(%)
|
-249.99
|
|
Operating margin(%)
|
-10834.19
|
|
Net Margin(%)
|
-12718.26
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Aclarion Inc (ACON) was $0 Mln.
$0.04
(
